Gunaratnam Mekala, Greciano Olga, Martins Cristina, Reszka Anthony P, Schultes Christoph M, Morjani Hamid, Riou Jean-Francois, Neidle Stephen
CRUK Biomolecular Structure Group, The School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Biochem Pharmacol. 2007 Sep 1;74(5):679-89. doi: 10.1016/j.bcp.2007.06.011. Epub 2007 Jun 16.
The trisubstituted acridine compound BRACO-19 has been developed as a ligand for stabilising G-quadruplex structures. It is shown here that BRACO-19 produces short- and long-term growth arrest in cancer cell lines, and is significantly less potent in a normal cell line. BRACO-19 reduces telomerase activity and long-term telomere length attrition is observed. It is also shown that BRACO-19 binds to telomeric single-stranded overhang DNA, consistent with quadruplex formation, and the single-stranded protein hPOT1 has been shown to be displaced from the overhang in vitro and in cellular experiments. It is concluded that the cellular activity of BRACO-19 can be ascribed both to the uncapping of 3' telomere ends and to telomere shortening that may preferentially affect cells with short telomeres.
三取代吖啶化合物BRACO-19已被开发作为一种用于稳定G-四链体结构的配体。本文表明,BRACO-19在癌细胞系中产生短期和长期的生长停滞,而在正常细胞系中的效力显著较低。BRACO-19降低端粒酶活性,并观察到长期的端粒长度损耗。还表明,BRACO-19与端粒单链悬突DNA结合,这与四链体形成一致,并且在体外和细胞实验中已证明单链蛋白hPOT1从悬突中被取代。得出的结论是,BRACO-19的细胞活性既归因于3'端粒末端的去封端,也归因于端粒缩短,而端粒缩短可能优先影响端粒短的细胞。